Amani Kallel^1,2*, Daouda Dia^1,2, Manel Ben Halima³, Mohamed Bessem Hammami^1,2, Haifa Sanhaji^1,2, Mohamed Sami Mourali³ and Moncef Feki^1,2

¹University of Tunis El Manar, Faculty of Medicine of Tunis, LR99ES11, Tunis, Tunisia
²Laboratory of Biochemistry, Rabta Hospital, Tunis, Tunisia
³Department of Cardiology, Rabta Hospital, Tunis, Tunisia

*Corresponding Author: Amani Kallel, University of Tunis El Manar, Faculty of Medicine of Tunis, LR99ES11, Tunis, Tunisia.

Received: October 12, 2023; Published: February 06, 2024

Abstract

MicroRNA-499 (miR-499) is thought to play a cardioprotective role by inhibiting myocyte apoptosis. The study aimed to determine the allelic and genotypic frequencies of miR-499 rs3746444 A/G polymorphism and to investigate its association with myocardial infarction (MI) in the Tunisian population. The SNP was genotyped in 160 patients with myocardial infarction (MI) and 168 healthy controls using PCR-RFLP. Both AG (0.46 vs. 0.34; P = 0.02) and GG (0.15 vs. 0.06; P = 0.01) genotypes and G allele (0.38 vs. 0.23; P < 0.001) of the miR-499 rs3746444 A/G polymorphism were significantly more frequent in MI patients than controls. Carriers of the minor G allele (i.e., AG+GG genotypes) showed lower plasma triglyceride levels (1.86 ± 0.64 mmol/L vs. 2.24 ± 1.13, mmol/L; P = 0.002). The study showed that miR-499 gene rs3746444 A>G polymorphism is associated with MI in the Tunisian population. The minor G allele could be considered as a biomarker for MI susceptibility in this population.

 Keywords: Coronary Artery Disease; Myocardial Infarction; miR-499 Gene; rs3746444 Polymorphism; Epigenetics

References

1. Roth GA., et al. “Global, regional, and national burden of cardiovascular diseases for 10 causes, 1990 to 2015”. Journal of the American College of Cardiology 70 (2017): 1-25.
2. Münzel T., et al. “Environmental risk factors and cardiovascular diseases: a comprehensive expert review”. Cardiovascular Research 118 (2022): 2880-2902.
3. Colpaert RMW and Calore M. “Epigenetics and microRNAs in cardiovascular diseases”. Genomics 113 (2021): 540-551.
4. Saliminejad K., et al. “An overview of microRNAs: Biology, functions, therapeutics, and analysis methods”. Journal of Cellular Physiology 234 (2019): 5451-5465.
5. Pozniak T., et al. “Circulating microRNAs in Medicine”. International Journal of Molecular Sciences 23 (2022): 1-17.
6. Filipów S and Łaczmański Ł. “Blood Circulating miRNAs as Cancer Biomarkers for Diagnosis and Surgical Treatment Response”. Frontiers in Genetics 10 (2019): 1-7.
7. Jin F., et al. “Serum microRNA Profiles Serve as Novel Biomarkers for Autoimmune Diseases”. Frontiers in Immunology 9 (2018): 2381.
8. Kaur A., et al. “Systematic review of microRNA biomarkers in acute coronary syndrome and stable coronary artery disease”. Cardiovascular Research 116 (2020): 1113-1124.
9. Zhou S., et al. “miRNAS in cardiovascular diseases: potential biomarkers, therapeutic targets and challenges”. Acta Pharmacologica Sinica 39 (2018): 1073-1084.
10. Zilahi E., et al. “Dysregulated expression profile of myomiRs in the skeletal muscle of patients with polymyositis”. eJIFCC 30 (2019): 237-245.
11. Jayawardena TM., et al. “MicroRNA-mediated in vitro and in vivo direct reprogramming of cardiac fibroblasts to cardiomyocytes”. Circulation Research 110 (2012): 1465-1473.
12. Fawzy MS., et al. “Association of MIR-499a expression and seed region variant (rs3746444) with cardiovascular disease in Egyptian patients”. Acta Cardiology 73 (2018): 131-140.
13. Lu JY., et al. “Association between miR-499 rs3746444 polymorphism and coronary heart disease susceptibility: An evidence-based meta-analysis of 5063 cases and 4603 controls”. Gene 698 (2019): 34-40.
14. Agiannitopoulos K., et al. “miRNA polymorphisms and risk of premature coronary artery disease”. Hellenic Journal of Cardiology 62 (2021): 278-284.
15. Yang Y., et al. “Associations between genetic variations in microRNA and myocardial infarction susceptibility: a meta-analysis and systematic review”. Herz 47 (2022): 524-535.
16. Xiong X., et al. “A common variant in pre-miR-146 is associated with coronary artery disease risk and its mature miRNA expression”. Mutation Research/Fundamental and Molecular Mechanisms of Mutagenesis 761 (2014): 15-20.
17. Qiu H., et al. “Associations between microRNA polymorphisms and development of coronary artery disease: A case-control study”. DNA Cell Biology 39 (2020): 25-36.
18. Thygesen K., et al. “Fourth universal definition of myocardial infarction (2018)”. European Heart Journal 40 (2019): 237-269.
19. Oikawa S and Akimoto T. “Functional analysis of microRNAs in skeletal muscle”. In: Asakura, A. (Ed.), Skeletal Muscle Stem Cells, Methods in Molecular Biology. Springer US, New York, NY (2023): 339-349.
20. Tseng YW., et al. “Evaluation of Friedewald’s Formula for Plasma LDL-Cholesterol Estimation”. Clinical Laboratory 69 (2023): 855-857.
21. Zhi H., et al. “Polymorphisms of miRNAs genes are associated with the risk and prognosis of coronary artery disease”. Clinical Research Cardiology 101 (2012): 289-296.
22. Chen LB., et al. “A single nucleotide polymorphism located in microRNA-499a causes loss of function resulting in increased expression of osbpl1a and reduced serum HDL level”. Oncology Report 38 (2017): 3515-3521.
23. Jeon YJ., et al. “Association of the miR-146a , miR-149 , miR-196a2 , and miR-499 Polymorphisms With Ischemic Stroke and Silent Brain Infarction Risk”. Arteriosclerosis, Thrombosis, and Vascular Biology 33 (2013): 420-430.
24. Parveen F and Agrawal S. “Recurrent Miscarriage and Micro-RNA Among North Indian Women”. Reproductive Sciences 22 (2015): 410-415.
25. Labbaf A., et al. “The pre-mir-499 Variant rs3746444 May Contribute to Coronary Artery Disease Susceptibility: a Case-Control and Meta-Analysis Study”. Clinical Laboratory 63 (2017): 1-10.
26. Fazli M., et al. “Association Study of Non-Coding RNA miR-499 and miR196a2 Gene Polymorphisms with the Risk of Idiopathic Recurrent Pregnancy Loss”. Gene Cell Tissue In Press. 5 (2018): 1-5.
27. Sung JH., et al. “miRNA polymorphisms (miR-146a, miR-149, miR-196a2 and miR-499) are associated with the risk of coronary artery disease”. Molecular Medicine Reports 14 (2016): 2328-2342.
28. Weiqiang Chen., et al. “Hsa-mir-499 rs3746444 T/C Polymorphism is associated with increased risk of coronary artery disease in a Chinese population”. Acta Cardiologica Sinica 33 (2017): 34-40.
29. Kansakar U., et al. “Functional Role of microRNAs in Regulating Cardiomyocyte Death”. Cells 11 (2022): 1-13.
30. Ding W., et al. “A polymorphism rs3746444 within the pre-miR-499 alters the maturation of miR-499-5p and its antiapoptotic function”. Journal of Cellular and Molecular Medicine 22 (2018): 5418-5428.
31. Machowska M., et al. “Consequences of genetic variants in miRNA genes”. Computational and Structural Biotechnology Journal 20 (2022): 6443-6457.
32. Tan SC., et al. “Association between MIR499A rs3746444 polymorphism and breast cancer susceptibility: a meta-analysis”. Scientific Report 10 (2020): 1-10.
33. Liu C., et al. “Association between miR‐146a rs2910164, miR‐196a2 rs11614913, and miR‐499 rs3746444 polymorphisms and the risk of esophageal carcinoma: A case-control study”. Cancer Medicine 11 (2022): 3949-3959.
34. Jiang JK., et al. “Rs3746444 T>C locus in miR-499 increases the susceptibility to hepatocellular carcinoma: A meta-analysis 14812 subjects”. World Journal of Gastrointestinal Oncology 15 (2023): 171-185.
35. Tabasi F., et al. “Association of miR-499 Polymorphism and Its Regulatory Networks with Hashimoto Thyroiditis Susceptibility: A Population-Based Case-Control Study”. International Journal of Molecular Sciences 22 (2021): 1-21.
36. Kong X., et al. “Association between miRNA-499 gene polymorphism and autoimmune diseases: A meta-analysis”. PLOS ONE 17 (2022): 1-15.
37. Liu F., et al. “Associations of the miRNA-146a rs2910164 and the miRNA-499a rs3746444 Polymorphisms With Plasma Lipid Levels: A Meta-Analysis”. Frontiers in Genetics 12 (2021): 1-11.
38. Giuliani A., et al. “The Association between Single Nucleotide Polymorphisms, including miR-499a Genetic Variants, and Dyslipidemia in Subjects Treated with Pharmacological or Phytochemical Lipid-Lowering Agents”. International Journal of Molecular Sciences 23 (2022): 1-12.

Citation

Citation: Amani Kallel., et al. “Association of the MiR-499 Gene rs-3746444 A/G Polymorphism with the Myocardial Infarction in the Tunisian Population”.Acta Scientific Medical Sciences 8.3 (2024): 07-13.

Copyright

Copyright: © 2024 Amani Kallel., et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.